Click on a filter below to refine your search. Remove a filter to broaden your search.
41.5% of difficult-to-treat resistance episodes were treated exclusively with traditional agents.
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
The risk increased for severe and very severe hypocalcemia for female dialysis-dependent Medicare patients aged 65 years or older.
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.
Caps are associated with a reduction in insulin costs, mainly driven by patients enrolled in health savings accounts.
Compared with matched nonusers, gabapentinoid users have an increased risk across indications of epilepsy, neuropathic pain and other chronic pain.
During high-concentration capsaicin patch treatment, a significant decrease was seen in average daily morphine equivalent dose.